PDCD1 and triple-negative breast carcinoma: Moreover, in advanced triple-negative breast cancer (TNBC), patients exhibiting higher plasma levels of TIM-3 or CTLA-4 have shown better responses to anti-PD-1 immunotherapy combined with VEGFR-2 targeted treatments [48].